Sanofi India Ltd

Sanofi India Ltd

Sanofi India Ltd has received a Show Cause Notice from GST Authorities alleging misclassification of certain products, resulting in a proposed tax liability of Rs. 36,38,70,979 and a penalty of Rs. 36,38,70,979. The company is in the process of responding to the notice and does not envisage any adverse impact on its financials, operations, or other activities.

Sanofi India Ltd

Sanofi India Ltd has disclosed under Regulation 30 of the SEBI (LODR) Regulations that the company has received an order from the Deputy Commissioner, Central Goods & Service Tax, Division –IV, Margao-Goa, accepting the company's application for GST refund without adjusting outstanding demand of Rs.75,63,190 and sanctioning a refund of Rs.1,32,93,535.

Sanofi India Ltd

Sanofi India Ltd has disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that the Assistant Commissioner of Income Tax, TDS OSD TDS Circle 2(2), Mumbai has passed an order giving effect to the favourable action(s) taken, initiated or Appellate Order received from CIT(A) - 49, order(s) passed Mumbai dated 2nd July 2026 for AY 2019-20, dropping the proceedings initiated under Section 201 of the Income-tax Act, 1961 thereby deleting the demand of Rs. 72,71,510.

Sanofi India Ltd

Sanofi India Ltd announced unaudited financial results for the quarter and half year ended 30th June 2026, with a double-digit growth of 14% in the diabetes business, driven by innovative portfolio Toujeo and Soliqua. The company maintained a market leadership position with a 47% market share by value and volume acceleration of 6% with Lantus. The results were presented during an investor conference call on August 5, 2026.

Sanofi India Ltd

Sanofi India Ltd has uploaded the video recording of an investor/analyst call held on August 5, 2026, to discuss unaudited financial results for the quarter and half year ended June 30, 2026, on its website.

Sanofi India Ltd

Sanofi India Ltd has announced its unaudited financial results for the quarter and half year ended 30th June 2026, with total income from operations at ₹312.74 crore and net profit for the period at ₹45.14 crore.

Sanofi India Ltd

Sanofi India Ltd has announced its unaudited financial results for the quarter and half year ended 30th June 2026, showing a strong momentum in its diabetes business with a 8% increase in domestic sales and a 14% growth in public sector sales. The company has also reported a 7% increase in total income for the quarter and a 4% decrease in total income for the half year.

Sanofi India Ltd

Sanofi India Ltd has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to Q2 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Ltd

Sanofi India Ltd has announced its Q2 2026 financial results, with domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Ltd

Sanofi India Ltd announced its financial results for Q2 2026, reporting domestic net sales growth of 8% and total net sales growth of 6% compared to Q2 2025. The Insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by Lantus, Toujeo, and Apidra. Profit before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Ltd

Sanofi India Ltd has announced its Q2 2026 financial results, reporting 8% domestic net sales growth and 6% total net sales growth compared to Q2 2025. The company's insulin portfolio delivered double-digit growth of 14% for the second consecutive quarter, driven by strong performance of Lantus, Toujeo, and Apidra. Profits before tax and exceptional items increased 19% to INR 112 crores, with profit before tax as a percentage of net sales improving to 27%.

Sanofi India Ltd

Sanofi India Ltd reported its unaudited financial results for the quarter and half year ended 30th June 2026, with domestic net sales growth of 8% and total net sales growth of 6% compared to the second quarter of 2025. The company's profits before tax and exceptional items increased 19% to INR 112 crores, with a profit before tax as a percentage of net sales improving to 27% in Q2 2026.

Sanofi India Ltd

Sanofi India Ltd announced a change in senior management personnel, with Mr. Nakul Verma ceasing to be a Senior Management Personnel of the Company, effective July 31, 2026, due to his transition to another role within the Sanofi group.

Sanofi India Ltd

Sanofi India Ltd will hold an investor/analysts call on 5th August 2026 to discuss unaudited financial results for the quarter and half year ended 30th June 2026.

Sanofi India Ltd

Sanofi India Ltd announces the resignation of Mr. Rachid Ayari as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel, effective September 30, 2026. The company appreciates his contributions and is in the process of identifying a suitable candidate for the CFO position.

Sanofi India Ltd

Sanofi India Ltd's Chief Financial Officer (CFO), Mr. Rachid Ayari, has resigned from his position, effective September 30, 2026, to transition to another role within the Sanofi group.

Sanofi India Ltd

Sanofi India Ltd announces change in management with Mr. Rachid Ayari stepping down as Whole Time Director, Chief Financial Officer, and Key Managerial Personnel effective September 30, 2026, due to transition to another role within the Sanofi group.

Sanofi India Ltd

Sanofi India Ltd announced that Mr. Rachid Ayari, Whole Time Director, Chief Financial Officer and Key Managerial Personnel, will step down from his current role effective September 30, 2026, to transition to another role within the Sanofi group. The company is in the process of identifying a suitable candidate for the position of Chief Financial Officer.